Ultrahuman

Ultrahuman is the rarest thing in consumer hardware: a fast-growing, profitable challenger. Revenue for FY25 (ended March 2025) reached roughly INR 565 crore (~$64M), up about fivefold year-over-year, with INR 73 crore of net profit — and the company has since been reported at an annualized run-rate around $150M, all achieved on roughly $103M of lifetime funding, a capital efficiency Whoop and Oura cannot claim. The metabolism-first stack is genuinely differentiated: Ring AIR (sold without the mandatory subscription that taxes Oura owners), the M1 continuous glucose monitor, the Blood Vision biomarker panel, and the Ultrahuman Home ambient monitor feed one app, positioning the company as a full-stack metabolic platform rather than a sleep tracker. Its response to the Oura patent war showed operational teeth: after the ITC exclusion order took effect in October 2025, Ultrahuman unveiled the redesigned Ring Pro in February 2026, secured US Customs and Border Protection clearance that its new architecture sits outside the banned design, opened US pre-orders in March at $399, and began shipping in May — restoring access to the largest premium market within months, while pursuing an appeal and a PTAB validity challenge against Oura's patent. India's engineering cost base, in-house manufacturing ambitions, and strength in markets Oura underserves (India, the Gulf, Southeast Asia) give it room to compound outside the US battleground, and reports of a fresh Series C of roughly Rs 400 crore (~$48M) suggest growth capital is available. Profitable, diversified, and back on American shelves, Ultrahuman is the credible second pole in a category that badly needs one.

Ultrahuman spent the crucial 2025 holiday season banned from the world's most important wearables market, and the wounds from how that happened may outlast the ban itself. The ITC's September 2025 ruling found its rings infringed Oura's patent, with exclusion and cease-and-desist orders effective October 21, 2025 — and the proceedings produced something worse than a patent loss: findings, highlighted in the Commission process, that Ultrahuman had presented falsified evidence of a Texas manufacturing facility, a credibility stain that follows the company into every future courtroom, diligence process, and partnership negotiation. RingConn, its co-defendant, took a license and settled; Ultrahuman chose the expensive path — appeals, a PTAB challenge, counter-suits — meaning open-ended legal spend against Oura, a far larger rival (valued at $5.2B as of late 2024) that has now demonstrated both the will and the ability to weaponize its patent estate, with district-court damages exposure still live. The Ring Pro workaround restores US access but at a cost structure and price ($399) that must fight Oura's brand dominance, Samsung's Galaxy Ring bundling, and a wave of cheap Chinese rings, while the redesign's legal safety remains Oura's to test. The financial narrative has soft spots: FY25's fivefold growth came off a small base; the reported ~$48M Series C arrived amid public confusion, with the CEO denying the reported lead investor; and the November 2025 raise was venture debt — an instrument profitable companies in favor rarely need. Diversification into CGMs (on Abbott's sensors), blood panels, and home devices spreads a modest R&D budget across four fronts against specialists in each. Profitability is real but thin; one more legal setback or a US demand miss puts it at risk.